{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:15:14Z","timestamp":1773332114448,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,30]]},"DOI":"10.7759\/cureus.13002","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T14:16:22Z","timestamp":1612016182000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines"],"prefix":"10.7759","author":[{"given":"Mariah","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth V","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Balani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel R","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea Mae N","family":"Nobleza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Migraine prevalence. A review of population-based studies","volume":"44","author":"Stewart WF","year":"1994","unstructured":"Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994, 44:17-23.","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"Migraine: multiple processes, complex pathophysiology","volume":"35","author":"Burstein R","year":"2015","unstructured":"Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015, 35:6619-6629. 10.1523\/JNEUROSCI.0373-15.2015","journal-title":"J Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04168.x","article-title":"The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs","volume":"44","author":"Kelman L","year":"2004","unstructured":"Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004, 44:865-872. 10.1111\/j.1526-4610.2004.04168.x","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.07.021","article-title":"Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain","volume":"154","author":"Noseda R","year":"2013","unstructured":"Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013, 154:S44-S53. 10.1016\/j.pain.2013.07.021","journal-title":"Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-136","article-title":"Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model","volume":"8","author":"Bolay H","year":"2002","unstructured":"Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002, 8:136-142. 10.1038\/nm0202-136","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103929","article-title":"Neurochemical pathways that converge on thalamic trigeminovascular neurons: a potential substrate for modulation of migraine by sleep, food intake, stress, and anxiety","volume":"9","author":"Noseda R","year":"2014","unstructured":"Noseda R, Kainz V, Borsook D, Burstein R. Neurochemical pathways that converge on thalamic trigeminovascular neurons: a potential substrate for modulation of migraine by sleep, food intake, stress, and anxiety. PLoS One. 2014, 9:e103929. 10.1371\/journal.pone.0103929","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1002\/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N","article-title":"An association between migraine and cutaneous allodynia","volume":"47","author":"Burstein R","year":"2000","unstructured":"Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000, 47:614-624.","journal-title":"Ann Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles A","year":"2019","unstructured":"Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019, 394:1765-1774. 10.1016\/S0140-6736(19)32504-8","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0927-2","article-title":"Migraine induction with calcitonin gene-related peptide in patients from erenumab trials","volume":"19","author":"Christensen CE","year":"2018","unstructured":"Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain. 2018, 19:105-2018. 10.1186\/s10194-018-0927-2","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick DW","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, et al.. Ubrogepant for the treatment of migraine. N Engl J Med. 2019, 381:2230-2241. 10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4796","article-title":"The role of anti-calcitonin gene-related peptide in migraine and its implication in developing countries: a reasonable option to consider despite higher cost","volume":"11","author":"Akhtar A","year":"2019","unstructured":"Akhtar A. The role of anti-calcitonin gene-related peptide in migraine and its implication in developing countries: a reasonable option to consider despite higher cost. Cureus. 2019, 11:e4796. 10.7759\/cureus.4796","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00066.x","article-title":"Botulinum toxin type A as a migraine preventive treatment","volume":"40","author":"Silberstein S","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. J Head Face Pain. 2000, 40:445-450. 10.1046\/j.1526-4610.2000.00066.x","journal-title":"J Head Face Pain"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki KR","year":"2005","unstructured":"Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicology. 2005, 26:785-793. 10.1016\/j.neuro.2005.01.017","journal-title":"NeuroToxicology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200211001-00005","article-title":"Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction","volume":"18","author":"Lew MF","year":"2002","unstructured":"Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002, 18:S142-S146. 10.1097\/00002508-200211001-00005","journal-title":"Clin J Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine","volume":"55","author":"Russo AF","year":"2015","unstructured":"Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015, 55:533-552. 10.1146\/annurev-pharmtox-010814-124701","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurpra.2019.07.009","article-title":"Monoclonal antibodies to CGRP or its receptor for migraine prevention","volume":"15","author":"Moriarty M","year":"2019","unstructured":"Moriarty M. Monoclonal antibodies to CGRP or its receptor for migraine prevention. J Nurse Practitioners. 2019, 15:717-724. 10.1016\/j.nurpra.2019.07.009","journal-title":"J Nurse Practitioners"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190709204107","article-title":"Novelty in inflammation and immunomodulation in migraine","volume":"25","author":"Cavestro C","year":"2019","unstructured":"Cavestro C, Ferrero M, Mandrino S, Di Tavi M, Rota E. Novelty in inflammation and immunomodulation in migraine. Curr Pharm Des. 2019, 25:2919-2936. 10.2174\/1381612825666190709204107","journal-title":"Curr Pharm Des"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/164_2020_365","article-title":"The use of botulinum toxin in the management of headache disorders","volume":"263","author":"Yuan H","year":"2021","unstructured":"Yuan H, Silberstein SD. The use of botulinum toxin in the management of headache disorders. Handb Exp Pharmacol. 2021, 263:227-249. 10.1007\/164_2020_365","journal-title":"Handb Exp Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: clinical evidence and experience","volume":"10","author":"Escher CM","year":"2017","unstructured":"Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017, 10:127-135. 10.1177\/1756285616677005","journal-title":"Ther Adv Neurol Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7072659","article-title":"Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy, and safety","volume":"7","author":"Szok D","year":"2015","unstructured":"Szok D, Cs\u00e1ti A, V\u00e9csei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy, and safety. Toxins. 2015, 7:2659-2673. 10.3390\/toxins7072659","journal-title":"Toxins"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do TP","year":"2019","unstructured":"Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope?. J Headache Pain. 2019, 20:37. 10.1186\/s10194-019-0974-3","journal-title":"J Headache Pain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen M","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, et al.. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017, 18:96. 10.1186\/s10194-017-0807-1","journal-title":"J Headache Pain"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-0978-9","article-title":"A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience","volume":"118","author":"Yalinay Dikmen P","year":"2018","unstructured":"Yalinay Dikmen P, Kosak S, Ilgaz Aydinlar E, Sagduyu Kocaman A. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. Acta Neurol Belg. 2018, 118:475-484. 10.1007\/s13760-018-0978-9","journal-title":"Acta Neurol Belg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick DW","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, et al.. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010, 50:921-936. 10.1111\/j.1526-4610.2010.01678.x","journal-title":"Headache"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/jnn.0b013e3181aaa98f","article-title":"Botox treatment for migraine and chronic daily headache in adolescents","volume":"41","author":"Chan VW","year":"2009","unstructured":"Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs. 2009, 41:235-243. 10.1097\/jnn.0b013e3181aaa98f","journal-title":"J Neurosci Nurs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1783219","article-title":"Performance characterization of spring actuated auto-injector devices for Emgality and Aimovig","volume":"36","author":"Dou Z","year":"2020","unstructured":"Dou Z, Eshraghi J, Guo T, et al.. Performance characterization of spring actuated auto-injector devices for Emgality and Aimovig. Curr Med Res Opin. 2020, 36:1343-1354. 10.1080\/03007995.2020.1783219","journal-title":"Curr Med Res Opin"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun H","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, et al.. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016, 15:382-390. 10.1016\/S1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"key":"ref28","article-title":"CGRP monoclonal antibodies for chronic migraine prevention: evaluation of adverse effects using a checklist","volume":"19","author":"Robbins L","year":"2020","unstructured":"Robbins L, Phenicie B. CGRP monoclonal antibodies for chronic migraine prevention: evaluation of adverse effects using a checklist. Practical Pain Management.com. 2020, 19:58-62.","journal-title":"Practical Pain Management.com"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000818","article-title":"Anatomical look into onabotulinumtoxinA injection for chronic migraine headache","volume":"43","author":"Wu-Fienberg Y","year":"2018","unstructured":"Wu-Fienberg Y, Ansari H, Zardouz S, Narouze S, Blaha T, Swanson M, Totonchi A. Anatomical look into onabotulinumtoxinA injection for chronic migraine headache. Reg Anesth Pain Med. 2018, 43:869-874. 10.1097\/AAP.0000000000000818","journal-title":"Reg Anesth Pain Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/45074-comparing-the-efficacy-safety-and-superiority-of-calcitonin-gene-related-peptide-monoclonal-antibodies-and-botox-in-preventing-and-treating-migraines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:32Z","timestamp":1707506972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/45074-comparing-the-efficacy-safety-and-superiority-of-calcitonin-gene-related-peptide-monoclonal-antibodies-and-botox-in-preventing-and-treating-migraines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.13002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,30]]}}}